JOURNAL HOME CME HOME THIS MONTH PAST ISSUES ETOC COLLECTIONS
AUTHORS REVIEWERS EDITORIAL BOARD FEEDBACK RSS HELP
A&A International Anesthesia Research Society
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Taneja, R.
Right arrow Articles by Cheng, D. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Taneja, R.
Right arrow Articles by Cheng, D. C.
Related Collections
Right arrow Cardiovascular
Right arrow Equipment
Right arrow Pharmacology

Anesth Analg 2006;103:1370-1372
© 2006 International Anesthesia Research Society
doi: 10.1213/01.ane.0000223781.83906.1b

CARDIOVASCULAR ANESTHESIA

Con: Heparin-Bonded Cardiopulmonary Bypass Circuits Should Be Routine for All Cardiac Surgical Procedures

Ravi Taneja, MBBS, MD, FFARCSI, FRCA, and Davy CH Cheng, MD, MSc, FRCPC

From the Department of Anesthesia & Perioperative Medicine, London Health Sciences Centre/St. Joseph's Health Care, The University of Western Ontario, Cardiac Surgery Recovery Unit, London Health Sciences Centre, London, Ontario, Canada.

Address correspondence and reprint requests to Prof. Davy C. H. Cheng, Department of Anesthesia & Perioperative Medicine, London Health Sciences Centre, Room C3-172, 339 Windermere Road, London, ON Canada, N6A 5A5. Address e-mail to davy.cheng{at}lhsc.on.ca.

"The important thing in science is not so much to obtain new facts as to discover new ways of thinking about them."

—Sir William Bragg

Despite advances in the care of cardiac surgical patients over the past 50 years, we are still confronted with challenges similar to those that preoccupied our pioneers. Surgeons, anesthesiologists, and perfusionists alike have been concerned with exposure of blood to the extracorporeal circuit, which is inherently not as physiologic as the endothelial cell layer. Exposure of blood to any artificial surface promotes thrombogenicity and is potentially fatal, requiring adequate intraoperative anticoagulation. Over the years, heparin has remained the sine qua non for the conduct of cardiopulmonary bypass (CPB), and adequacy of anticoagulation has mostly required achieving a minimal target activated clotting time (ACT) rather than acquiring an optimal therapeutic level during surgery.

A number of reports have cited the successful use of various surface modifying agents on the extracorporeal circuits used in cardiac surgery (1–6). Of these, modifications of material surface through heparin immobilization (so-called "heparin-coated circuits") have been most ubiquitously investigated (7). There have been mixed reports regarding their efficacy as well as inefficacy (8–22). Interpretation of these results is difficult and may cause confusion about whether to use heparin-coated circuits for CPB. Certainly, their routine use has remained infrequent, as a survey in the United States shows that only a small proportion (17%) of centers routinely use heparin-coated circuits in cardiac surgery (23).

Historically, two principal mechanisms have been proposed for the beneficial effects of heparin-coated circuits (24,25):

  1. Improved biocompatibility of the circuit material leads to decreased activation of complement and leukocytes and, hence, a decreased systemic inflammatory response to CPB.
  2. Heparin immobilization also allows for its direct exposure to flowing blood, making the artificial surface more hydrophilic and biocompatible. This may help in augmenting the anticoagulation effect, inhibition of activation of thrombin and the fibrinolytic system, decreased coagulopathy, and, possibly, less perioperative bleeding.

The first point raises the most fundamental issue—that of the "systemic inflammatory response." The signs of a localized inflammatory response are well known (calor, rubor, dolor, tumor, and functio laesa), but what are the clinical features of a systemic inflammatory response and is it really harmful to the patient (26)? The systemic or generalized inflammatory response cannot as yet be characterized clinically in animal or human models. It only attracts a default diagnosis in critically ill patients who manifest high output syndromes and organ dysfunction in the presence of infection, shock, or trauma. Although the inflammatory response to CPB has been compared to systemic inflammatory response syndrome (SIRS) accompanying sepsis, there is no consensus on how to define it or evidence to suggest that its manifestation increases postoperative morbidity and mortality (27). Inflammation is crucial for wound healing and repair, and to imply that a generalized response is inappropriate highlights the gleam of only a single edge of this double-edged sword. Thus, to state that heparin-coated circuits decrease contact activation and systemic inflammatory response should attract little attention unless that translates into improved outcomes for our patients.

Initial investigations indicated an improvement in biochemical markers (28–30); and a few trials suggest an association between the use of heparin-bonded CPB circuits and decreased morbidity (8,9). One report further demonstrates that patients exposed to heparin-coated circuits have a decreased inflammatory response, reduced pulmonary vascular resistance, and improved Pao2/Fio2 ratios after surgery; however, this was not associated with a decreased lung ventilation time or intensive care unit stay (12). Another investigation suggests the use of heparin-bonded circuits during surgery to decrease postoperative neurocognitive dysfunction, but the authors did not find an association of this clinical effect with complement or coagulation activation (11). Postoperative organ dysfunction may not, however, be related to activation of the terminal complement complex, granulocyte activation, or to the use of heparin-coated circuits (28,31). Certain research groups have shown benefits with heparin-bonded circuits only when these have been used with other perfusion modifications such as reduced systemic heparin and avoidance of cardiotomy suction blood (2,9,32,33). Obviously, post-CPB morbidity and mortality may be related to many mechanisms other than the use of biocompatible circuits making it difficult to show a benefit based purely on alteration of one component of inflammation.

An early goal for heparin-bonded circuits was to increase thrombo-resistance because systemic heparin was believed to cause postoperative platelet dysfunction and fibrinolysis (34). Initial studies compared the effects of full (ACT > 480 s) versus reduced (ACT ~250 s) heparinization in conjunction with heparin-coated circuits. The reduced systemic anticoagulation protocol seemed safe and was associated with decreased postoperative bleeding, although not consistently (9,15,16,21,32,33,35,36). Postoperative chest tube drainage continues to occur almost uniformly after cardiac surgery and although its etiology may be multifactorial, microvascular coagulopathy remains the most common cause (37,38).

Microvascular coagulopathy also occurs in sepsis and multiple organ dysfunction syndrome. Initially thought to be a mere epiphenomenon, it is now believed to be a critical step in development of multiple organ dysfunction syndrome (39): central to this is thrombin and its regulatory anticoagulant protein C pathway (40). Thrombin has both procoagulant and proinflammatory effects, and its inappropriate regulation by activated protein C is associated with increased mortality (41,42). Thrombin levels also increase during cardiac surgery despite full anticoagulation with heparin (43–47). Patient-specific heparin dosing and its monitoring limit thrombin generation and consumption of coagulation factors associated with decreased transfusions in the postoperative period (48–51). Is it possible that the coagulopathy after cardiac surgery is a manifestation of the host inflammatory response? Could the risk of postoperative hemorrhage be further decreased with a more precise anticoagulation protocol in combination with heparin-bonded circuits? Future investigations may need to evaluate different thrombin inhibitors that are used in conjunction with biocompatible circuits with clinically relevant end-points.

Heparin-coated circuits have cost implications as well. Currently, at the London Health Sciences Centre, London, Ontario, the use of heparin-coated circuits would offset the case costing by more than C$150 per CPB surgery. In a managed health care environment, the added expense could only be justified if it leads to a reduction in morbidity and mortality.

In summary, heparin-coated circuits are proposed to improve biocompatibility by reducing coagulation and inflammatory activation, neither of which have been universally demonstrated. Organ dysfunction after cardiac surgery is likely multifactorial in etiology, and a direct benefit on patient outcome by attenuating inflammation to CPB is yet to be established. Many questions regarding the use of heparin-coated circuits need to be addressed before their use becomes routine, including the extent of systemic anticoagulation. There is no doubt that advances in technology will herald more physiological but complex biocompatible materials on CPB circuits. However, justifying the added expense of this technology will require data showing that patient outcomes are improved and not just that its use is associated with alteration of surrogate markers of organ injury.


   Footnotes
 
Accepted for publication April 4, 2006.


   REFERENCES
Top
 REFERENCES
 

  1. Shimamoto A, Kanemitsu S, Fujinaga K, et al. Biocompatibility of silicone-coated oxygenator in cardiopulmonary bypass. Ann Thorac Surg 2000;69:115–20.[Abstract/Free Full Text]
  2. Ovrum E, Tangen G, Oystese R, et al. Comparison of two heparin-coated extracorporeal circuits with reduced systemic anticoagulation in routine coronary artery bypass operations. J Thorac Cardiovasc Surg 2001;121:324–30.[ISI][Medline]
  3. Ereth MH, Nuttall GA, Clarke SH, et al. Biocompatibility of trillium biopassive surface-coated oxygenator versus uncoated oxygenator during cardiopulmonary bypass. J Cardiothorac Vasc Anesth 2001;15:545–50.[ISI][Medline]
  4. Ikuta T, Fujii H, Shibata T, et al. A new poly-2-methoxyethylacrylate-coated cardiopulmonary bypass circuit possesses superior platelet preservation and inflammatory suppression efficacy. Ann Thorac Surg 2004;77:1678–83.[Abstract/Free Full Text]
  5. Defraigne JO, Pincemail J, Dekoster G, et al. SMA circuits reduce platelet consumption and platelet factor release during cardiac surgery. Ann Thorac Surg 2000;70:2075–81.[Abstract/Free Full Text]
  6. Ueyama K, Nishimura K, Nishina T, et al. PMEA coating of pump circuit and oxygenator may attenuate the early systemic inflammatory response in cardiopulmonary bypass surgery. ASAIO J 2004;50:369–72.[ISI][Medline]
  7. Gott VL, Whiffen JD, Duttron RC. Heparin bonding on colloidal graphite surfaces. Science 1963;142:1297–8.[Abstract/Free Full Text]
  8. Ranucci M, Mazzucco A, Pessotto R, et al. Heparin-coated circuits for high-risk patients: a multicenter, prospective, randomized trial. Ann Thorac Surg 1999;67:994–1000.[Abstract/Free Full Text]
  9. Aldea GS, Doursounian M, O'Gara P, et al. Heparin-bonded circuits with a reduced anticoagulation protocol in primary CABG: a prospective, randomized study. Ann Thorac Surg 1996;62:410–7.[Abstract/Free Full Text]
  10. Svenmarker S, Haggmark S, Jansson E, et al. Use of heparin-bonded circuits in cardiopulmonary bypass improves clinical outcome. Scand Cardiovasc J 2002;36:241–6.[ISI][Medline]
  11. Heyer EJ, Lee KS, Manspeizer HE, et al. Heparin-bonded cardiopulmonary bypass circuits reduce cognitive dysfunction. J Cardiothorac Vasc Anesth 2002;16:37–42.[ISI][Medline]
  12. de Vroege R, van Oeveren W, van Klarenbosch J, et al. The impact of heparin-coated cardiopulmonary bypass circuits on pulmonary function and the release of inflammatory mediators. Anesth Analg 2004;98:1586–94.[Abstract/Free Full Text]
  13. Grossi EA, Kallenbach K, Chau S, et al. Impact of heparin bonding on pediatric cardiopulmonary bypass: a prospective randomized study. Ann Thorac Surg 2000;70:191–6.[Abstract/Free Full Text]
  14. Wan S, LeClerc JL, Antoine M, et al. Heparin-coated circuits reduce myocardial injury in heart or heart-lung transplantation: a prospective, randomized study. Ann Thorac Surg 1999;68:1230–5.[Abstract/Free Full Text]
  15. Oliver WCJ, Nuttall GA, Ereth MH, et al. Heparin-coated versus uncoated extracorporeal circuit in patients undergoing coronary artery bypass graft surgery. J Cardiothorac Vasc Anesth 2003;17:165–70.[ISI][Medline]
  16. Wildevuur CR, Jansen PG, Bezemer PD, et al. Clinical evaluation of Duraflo II heparin treated extracorporeal circulation circuits (2nd version). The European Working Group on heparin coated extracorporeal circulation circuits. Eur J Cardiothorac Surg 1997;11:616–23.[Abstract]
  17. Flom-Halvorsen HI, Ovrum E, Brosstad F, et al. Effects of two differently heparin-coated extracorporeal circuits on markers for brain and myocardial dysfunction. Perfusion 2002;17:339–45.[Abstract/Free Full Text]
  18. Lundblad R, Moen O, Fosse E. Endothelin-1 and neutrophil activation during heparin-coated cardiopulmonary bypass. Ann Thorac Surg 1997;63:1361–7.[Abstract/Free Full Text]
  19. Belboul A, Akbar O, Lofgren C, et al. Improved blood cellular biocompatibility with heparin coated circuits during cardiopulmonary bypass. J Cardiovasc Surg (Torino) 2000;41:357–62.[Medline]
  20. Belboul A, Lofgren C, Storm C, Jungbeck M. Heparin-coated circuits reduce occult myocardial damage during CPB: a randomized, single blind clinical trial. Eur J Cardiothorac Surg 2000;17:580–6.[Abstract/Free Full Text]
  21. Videm V, Mollnes TE, Bergh K, et al. Heparin-coated cardiopulmonary bypass equipment. II. Mechanisms for reduced complement activation in vivo. J Thorac Cardiovasc Surg 1999;117:803–9.[Abstract/Free Full Text]
  22. Jansen PG, Baufreton C, Le Besnerais P, et al. Heparin-coated circuits and aprotinin prime for coronary artery bypass grafting. Ann Thorac Surg 1996;61:1363–6.[Abstract/Free Full Text]
  23. Mejak BL, Stammers A, Rauch E, et al. A retrospective study on perfusion incidents and safety devices. Perfusion 2000;15:51–61.[Abstract/Free Full Text]
  24. von Segesser LK, Weiss BM, Garcia E, et al. Reduction and elimination of systemic heparinization during cardiopulmonary bypass. J Thorac Cardiovasc Surg 1992;103:790–8.[Abstract]
  25. Matheve C. Clinical evidence of improved biocompatibility using heparin-coated surfaces. Perfusion 1996;11:264–9.[Free Full Text]
  26. Laffey JG, Boylan JF, Cheng DC. The systemic inflammatory response to cardiac surgery: implications for the anesthesiologist. Anesthesiology 2002;97:215–52.[ISI][Medline]
  27. Johnson MR. Low systemic vascular resistance after cardiopulmonary bypass: are we any closer to understanding the enigma? Crit Care Med 1999;27:1048–50.[ISI][Medline]
  28. Videm V, Mollnes TE, Fosse E, et al. Heparin-coated cardiopulmonary bypass equipment. I. Biocompatibility markers and development of complications in a high-risk population. J Thorac Cardiovasc Surg 1999;117:794–802.[Abstract/Free Full Text]
  29. Videm V, Svennevig JL, Fosse E, et al. Reduced complement activation with heparin-coated oxygenator and tubings in coronary bypass operations. J Thorac Cardiovasc Surg 1992;103:806–13.[Abstract]
  30. Hatori N, Yoshizu H, Haga Y, et al. Biocompatibility of heparin-coated membrane oxygenator during cardiopulmonary bypass. Artif Organs 1994;18:904–10.[ISI][Medline]
  31. Johnson MR. Low systemic vascular resistance after cardiopulmonary bypass: are we any closer to understanding the enigma? Crit Care Med 1999;27:1048–50.[ISI][Medline]
  32. Ovrum E, Holen EA, Tangen G, et al. Completely heparinized cardiopulmonary bypass and reduced systemic heparin: clinical and hemostatic effects. Ann Thorac Surg 1995;60:365–71.[Abstract/Free Full Text]
  33. von Segesser LK, Weiss BM, Pasic M, et al. Risk and benefit of low systemic heparinization during open heart operations. Ann Thorac Surg 1994;58:391–7.[Abstract]
  34. Khuri SF, Valeri CR, Loscalzo J, et al. Heparin causes platelet dysfunction and induces fibrinolysis before cardiopulmonary bypass. Ann Thorac Surg 1995;60:1008–14.[Abstract/Free Full Text]
  35. Weiss BM, von Segesser LK, Turina MI, et al. Perioperative course and recovery after heparin-coated cardiopulmonary bypass: low-dose versus high-dose heparin management. J Cardiothorac Vasc Anesth 1996;10:464–70.[ISI][Medline]
  36. Borowiec J, Thelin S, Bagge L, et al. Decreased blood loss after cardiopulmonary bypass using heparin-coated circuit and 50% reduction of heparin dose. Scand J Thorac Cardiovasc Surg 1992;26:177–85.[ISI][Medline]
  37. Parr KG, Patel MA, Dekker R, et al. Multivariate predictors of blood product use in cardiac surgery. J Cardiothorac Vasc Anesth 2003;17:176–81.[ISI][Medline]
  38. Moulton MJ, Creswell LL, Mackey ME, et al. Reexploration for bleeding is a risk factor for adverse outcomes after cardiac operations. J Thorac Cardiovasc Surg 1996;111:1037–46.[Abstract/Free Full Text]
  39. Marshall JC. Inflammation, coagulopathy, and the pathogenesis of multiple organ dysfunction syndrome. Crit Care Med 2001;29:S99–106.[ISI][Medline]
  40. Esmon C. The protein C pathway. Crit Care Med 2000;28:S44–8.[ISI][Medline]
  41. Liaw PC, Esmon CT, Kahnamoui K, et al. Patients with severe sepsis vary markedly in their ability to generate activate protein C. Blood 2004;104:3958–64.[Abstract/Free Full Text]
  42. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699–709.[Abstract/Free Full Text]
  43. Despotis GJ, Gravlee G, Filos K, Levy J. Anticoagulation monitoring during cardiac surgery: a review of current and emerging techniques. Anesthesiology 1999;91:1122–51.[ISI][Medline]
  44. Jobes DR, Aitken GL, Shaffer GW. Increased accuracy and precision of heparin and protamine dosing reduces blood loss and transfusion in patients undergoing primary cardiac operations. J Thorac Cardiovasc Surg 1995;110:36–45.[Abstract/Free Full Text]
  45. Slaughter TF, LeBleu TH, Douglas JMJ, et al. Characterization of prothrombin activation during cardiac surgery by hemostatic molecular markers. Anesthesiology 1994;80:520–6.[ISI][Medline]
  46. Chandler WL, Velan T. Estimating the rate of thrombin and fibrin generation in vivo during cardiopulmonary bypass. Blood 2003;101:4355–62.[Abstract/Free Full Text]
  47. Boisclair MD, Lane DA, Philippou H, et al. Mechanisms of thrombin generation during surgery and cardiopulmonary bypass. Blood 1993;82:3350–7.[Abstract/Free Full Text]
  48. Koster A, Fischer T, Praus M, et al. Hemostatic activation and inflammatory response during cardiopulmonary bypass: impact of heparin management. Anesthesiology 2002;97:837–41.[ISI][Medline]
  49. Despotis GJ, Joist JH, Hogue CWJ, et al. More effective suppression of hemostatic system activation in patients undergoing cardiac surgery by heparin dosing based on heparin blood concentrations rather than ACT. Thromb Haemost 1996;76:902–8.[ISI][Medline]
  50. Despotis GJ, Joist JH, Hogue CWJ, et al. The impact of heparin concentration and activated clotting time monitoring on blood conservation: a prospective, randomized evaluation in patients undergoing cardiac operation. J Thorac Cardiovasc Surg 1995;110:46–54.[Abstract/Free Full Text]
  51. Jobes DR, Aitken GL, Shaffer GW. Increased accuracy and precision of heparin and protamine dosing reduces blood loss and transfusion in patients undergoing primary cardiac operations. J Thorac Cardiovasc Surg 1995;110:36–45.[Abstract/Free Full Text]




This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Taneja, R.
Right arrow Articles by Cheng, D. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Taneja, R.
Right arrow Articles by Cheng, D. C.
Related Collections
Right arrow Cardiovascular
Right arrow Equipment
Right arrow Pharmacology

Lippincott, Williams & Wilkins Anesthesia & Analgesia® is published for the International Anesthesia Research Society® by Lippincott Williams & Wilkins with the assistance of Stanford University Libraries' HighWire Press®. Copyright 2006 by the International Anesthesia Research Society. Online ISSN: 1526-7598   Print ISSN: 0003-2999 HighWire Press